Aprea Therapeutics appoints John Hamill as CFO, replacing Scott Coiante

Aprea Therapeutics, Inc.

John Hamill appointed CFO effective Jan 30, 2023; succeeds Scott Coiante who remains through March 31.
Hamill brings over 30 years finance experience; previously CFO at Windtree Therapeutics, Trevena, NephroGenex.
Compensation: $420k base salary, 40% target bonus, $50k sign-on bonus (payable March 2024).
Equity grant: options for 539,758 shares (4-year vest) and RSUs for 269,879 shares (3-year vest).
Coiante receives 12 months base salary and health benefits under separation agreement.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Scott Coiante

Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer

APRE · Aprea Therapeutics, Inc.

Effective: 2023-01-30
Successor: John Hamill
Filed: January 30, 2023, 6:59 PM ET

Mr. Hamill will replace Scott Coiante, who will step down from his role as Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective as of the Transition Date.

Appointed

John Hamill

Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer

APRE · Aprea Therapeutics, Inc.

Effective: 2023-01-30
Filed: January 30, 2023, 6:59 PM ET

Effective January 30, 2023 (the “Transition Date”), John Hamill became Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer of Aprea Therapeutics, Inc.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Scott Coiante departed as Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer at Aprea Therapeutics, Inc..

Action: stepped down
Role: Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer

Exact text from the filing

Mr. Hamill will replace Scott Coiante, who will step down from his role as Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective as of the Transition Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

John Hamill was appointed as Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer at Aprea Therapeutics, Inc..

Action: appointed
Role: Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer

Exact text from the filing

Effective January 30, 2023 (the “Transition Date”), John Hamill became Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer of Aprea Therapeutics, Inc.

View on SEC.gov

Aprea Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-008020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.